Glenzocimab (Synonyms: ACT017) |
| Katalog-Nr.GC69164 |
Glenzocimab (ACT017) is a humanized monoclonal antibody Fab fragment against GPVI. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential to be studied for acute ischemic stroke.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2101829-58-5
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Review for Glenzocimab
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
Review for Glenzocimab
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *